Recently, Agatroban, which was declared by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang No.4 Pharmaceutical Group, was approved by the State Drug Administration to be registered as an API for listed preparations.

It is understood that Agatroban is a new generation of anticoagulant, which belongs to small molecule direct thrombin inhibitor. Its preparation is mainly used for clinical treatment of peripheral arterial occlusive diseases and prevention or treatment of arterial thrombosis.

Focusing on the business development strategy of "API+preparation", Shijiazhuang No.4 Pharmaceutical Group has vigorously implemented the chain extension and chain reinforcement of leading industries, and made positive progress in the research and development of characteristic preparations and APIs. Since this year, 26 approvals for various products have been obtained, including 16 kinds of preparations, 10 kinds of APIs, and 4 kinds of preparations are the first domestic pharmaceutical enterprises to be approved.